<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520260</url>
  </required_header>
  <id_info>
    <org_study_id>Sch012007</org_study_id>
    <nct_id>NCT00520260</nct_id>
  </id_info>
  <brief_title>Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase</brief_title>
  <official_title>Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Eye Microsurgical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida Eye Microsurgical Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare bromfenac 0.09% and ketorolac 0.4% when used concomitantly with cyclosporine
      ophthalmic emulsion 0.05% in improving patient comfort during the induction phase of
      treatment for chronic dry eye disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular comfort</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Dry Eye Disease</condition>
  <condition>Ocular Comfort</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment arm bromfenac 0.09% BID for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketorolac 0.4% BID for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bromfenac</intervention_name>
    <description>0.09%, BID, 6 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketorolac</intervention_name>
    <description>0.4%, BID, 6 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be in general good health

          -  Diagnosis of moderate to severe dry eye syndrome

        Exclusion Criteria:

          -  Patients who are unlikely to respond to cyclosporine ophthalmic emulsion therapy

          -  Patients who are pregnant or nursing females

          -  Unwilling to discontinue use of contact lenses during the run-in and duration of the
             study

          -  Presence or history of any systemic or ocular disorder or condition that could
             possibly interfere with the interpretation of the study results in the study eye

          -  Previous treatment failure on CSA 0.05% (Restasis)

          -  Known hypersensitivity to any component of the study or procedural medications

          -  Participation in any other clinical trial within 30 days prior to screening

          -  Known contraindication to any study medication or any of their components.

          -  Should not be taking any oral anti-histamines, beta blockers or diuretics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Schechter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Eye Microsurgical Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Eye Microsurgical Institute</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2007</study_first_submitted>
  <study_first_submitted_qc>August 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2007</study_first_posted>
  <last_update_submitted>February 17, 2009</last_update_submitted>
  <last_update_submitted_qc>February 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Barry Schechter, MD</name_title>
    <organization>Florida Eye Microsurgical Institute</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 14, 2012</submitted>
    <returned>April 9, 2012</returned>
    <submitted>April 18, 2012</submitted>
    <returned>May 15, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

